Anti-IMP3 antibody [RP23040260],Abcam,AB313556

What are recombinant multiclonals? Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including: - The sensitivity of polyclonal antibodies by recognising multiple epitopes - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production View our range of recombinant multiclonal antibodies .

Host

Rabbit

Reactivity

Human

Application

ICC/IF, RIP

Platform ID

BAB604898918

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-IMP3 antibody [RP23040260]
Cat. No.AB313556
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationICC/IF, RIP
ClonalityMulticlonal
Concentration0.5 mg/mL Batch dependent concentration
ImmunogenSynthetic Peptide within Human IGF2BP3.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.09% Sodium azide Constituents: 99.91% PBS
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data RNA-binding factor that may recruit target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation. Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed : 29476152). Binds to the 3'-UTR of CD44 mRNA and stabilizes it, hence promotes cell adhesion and invadopodia formation in cancer cells. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD (PubMed : 29476152). Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs. See full target information IGF2BP3

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.